Saliva sample for detection of SARS-CoV-2: A possible alternative for mass testing

Olumuyiwa Babalola Salu1,2*, Iorhen Ephraim Akase3*, Roosevelt Amaobichukwu Anyanwu1†, Mercy Remilekun Orenolu1†, Maryam Abiodun Abdullah1†, Temie Giwa-Tubosun4*, Sodiq Abiodun Oloko4†, Ayomide Michael Oshinjo4*, Aisha Ajobi Abiola4†, Kolawole Solomon Oyedeji1,5*, Sunday Aremu Omilabu1,2*,

1 Centre for Human and Zoonotic Virology, Central Research Laboratory, College of Medicine of the University of Lagos, Ida-Araba, Lagos, Nigeria, 2 Department of Medical Microbiology and Parasitology, College of Medicine of the University of Lagos, Ida-Araba, Lagos, Nigeria, 3 Department of Medicine, Infectious Disease Unit, Lagos University Teaching, Ida-Araba, Lagos State, Nigeria, 4 Research and Development Unit, LifeBank, Yaba, Lagos, Nigeria, 5 Department of Medical Laboratory Science, College of Medicine of the University of Lagos, Ida-Araba, Lagos, Nigeria.

These authors contributed equally to this work.
† RAA, MRO, MAA, TGT, SAO, AMO and AAA also contributed equally to this work.
*
obalu@yahoo.com

Abstract

Molecular diagnostic testing has played a critical role in the global response to the novel Coronavirus disease (COVID-19) pandemic, since its first outbreak in late 2019. At the inception of the COVID-19 pandemic, nasopharyngeal swab sample analysis for COVID-19 diagnosis using the real-time polymerase chain reaction (RT-PCR) technique was the most widely used. However, due to the high cost and difficulty of sample collection, the number of available sample types for COVID-19 diagnosis is rapidly increasing, and is the COVID-19 diagnostic literature. The use of nasal swabs, saliva, and oral fluids as viable sample options for the effective detection of SARS-CoV-2 has been implemented successfully in different settings since 2020. These alternative sample type provides a plethora of advantages including decreasing the high exposure risk to frontline workers, enhancing the chances of home self-sampling, reducing the cost, and significantly increasing testing capacity. This study sought to ascertain the effectiveness of Saliva samples as an alternative for COVID-19 diagnosis in Nigeria. Demographic data, paired samples of Nasopharyngeal Swab and Drooling Saliva were obtained from 309 consenting individuals aged 8–83 years presenting for COVID-19 testing. All samples were simultaneously assayed for the detection of SARS-CoV-2 RdRp, N, and E genes using the GeneFinder™ COVID-19 Plus RT-PCR test kit. Out of 309 participants, only 299 with valid RT-PCR results comprising 159 (53.2%) males and 140 (46.8%) females were analyzed in this study using the R Statistical package. Among the 299 samples analyzed, 39 (13.0%) had SARS-CoV-2 detected in at least one specimen type. Both swabs and saliva were positive in 20 (51.3%) participants. Ten participants (25.6%) had swab positive/saliva-negative results and 9 participants (23.1%) had saliva positive/swab-negative results. The percentage of positive and negative agreement of the saliva samples with the nasopharyngeal swab were 67% and 97% respectively with positive and negative predictive values as 69% and 96% respectively. The findings indicate that...
Introduction

A novel coronavirus disease was identified in Wuhan, China, in December 2019 [1]. The infectious agent was later named to be Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). COVID-19 became a global pandemic in March 2020 with a fatality rate of 2–3% [2]. This ongoing COVID-19 pandemic has had an unprecedented impact on the healthcare, economic and social structure across the geographic regions of the world [3, 4]. Globally, there have been over 610 million laboratory-confirmed cases of COVID-19 and about 6.5 million deaths (as of 5th September 2022) and widespread testing remains a major tool in identifying individuals infected with SARS-CoV-2 as it influences the management and control strategies in combating the pandemic [4]. To effectively control the COVID-19 outbreak, it is essential to identify a convenient yet effective means of sampling and diagnosis.

Specialized trained personnel or healthcare workers (HCWs) are required to perform oropharyngeal swabs (OPS) and nasopharyngeal swabs (NPS) sample collection with increasingly close contact with the patients. This sample collection method leads to an increased biosafety risk to healthcare professionals via aerosol droplet transmission coupled with reported cases of bleeding and a higher incidence of discomfort for patients [5]. However, since the SARS-CoV-2 RNA has been detected in the saliva of infected patients and oral transmission of COVID-19 has also been suggested [6–9]. Therefore, the saliva sample could be a good alternative as it’s been shown to be an effective biological sample for carrying out viral detection methods [10].

The use of Saliva samples for the detection of SARS-CoV-2 had already been launched in some niches and the US Food and Drug Administration had given an emergency use authorization for saliva-based protocol [11–15]. Saliva sample collection is also a less traumatic/invasive procedure, particularly in pediatric patients [16].

Based on these issues and others including the need for faster mass testing while managing limited resources, it is critical to find a safe, viable, and cost-effective sample collection method. Saliva seems to be a potentially viable substitute with comparable accuracy and reliability to pharyngeal swab collection which can easily be gotten from patients’ passive drool into a sterile container [17, 18]. Aside from these benefits, saliva samples can be collected by the patients themselves without the intervention of any professional. With a self-sample collection structure, personal protective equipment which is increasingly scarce and expensive will only be needed in the direct provision of care. This reduces strain on available human and financial resources and increases capacity for testing [18].

There is a growing wealth of data with varying diagnostic accuracy on the successful use and implementation of saliva samples for SARS-CoV-2 detection using RT-PCR techniques around the world [19–31]. The collection methods and timing of saliva greatly influence the outcome of the testing depending on the collection method. Saliva is a complex bio-mixture that can consist of salivary gland secretion, gingival crevicular fluid, sputum, and/or mucosal transudate, in varying proportions serving as shortcomings to the testing outcomes [32]. Therefore, these shortcomings in the use of saliva samples need to be considered during testing. Also, some sick or dehydrated patients, who produce thick saliva samples. The saliva samples might be difficult to pipet during sample analysis and require that the technician handling such must be well experienced in dealing with such samples [33, 34]. Special care should also be taken when dealing with children’s saliva samples since a lower sensitivity has been reported.
This study was carried out to assess the diagnostic efficacy and sensitivity of self-collected saliva specimens as compared to Nasopharyngeal swabs for the detection of SARS-CoV-2 in Lagos University Teaching Hospital, Lagos State, Nigeria using reverse transcription-polymerase chain reaction (RT-PCR).

### Materials and methods

#### Study location/area

This study was carried out at the COVID-19 sampling collection site of the Lagos University Teaching Hospital (LUTH), which is one of the Nigerian Centre for Disease Control (NCDC) and the Federal Ministry of Health (FMoH) designated facilities for the treatment and management of COVID-19. The Lagos University Teaching Hospital is a tertiary hospital established in 1961 and is located in Idi-Araba, Surulere, Lagos State; the economic hub of Nigeria [37]. The teaching hospital is affiliated with the College of Medicine of the University of Lagos (CMUL) which was established in 1962. The CMUL trains medical/paramedical students, while LUTH provides them with clinical experience. The Lagos University Teaching Hospital is the largest in Nigeria with 761 beds [37] providing medical services to the over 20 million population of Lagos State and other states in the country.

#### Study design and population

This was a cross-sectional study conducted between 1st March and 10th April 2021 involving a total of 309 consenting individuals aged 8 to 83 years (mean age = 36.33yrs) who presented for COVID-19 testing at the LUTH sample collection site in Lagos, Nigeria.

#### Ethical consideration

Ethical approval was obtained from the Health Research and Ethics Committee of the College of Medicine of the University of Lagos (HREC, CMUL) with approval number CMUL/HREC/11/20/793. Written consent was obtained from adult participants after due explanations and understanding of the purpose of the study. Consent was obtained from the parents/guardian of minors using a similar approach.

#### Specimen collection, transportation, handling, and processing

Demographic data, paired samples of Nasopharyngeal Swab in Universal Viral Transport Media (VTM) (309 vials), and Drooling Saliva in sterile containers (309 vials) were obtained from the consenting individuals in this study. Saliva samples were self-collected under the observation of a healthcare worker (sample collector) who subsequently collected the Nasopharyngeal swab. Each participant was asked to work up saliva by gently rubbing the outside of their cheeks and gently spitting without coughing or clearing their throats into a sterile universal container.

Samples were transported in the cold chain using triple-level packaging, from the collection site in LUTH to the Centre for Human and Zoonotic Virology (CHAVZVY), Central Research Laboratory, College of Medicine of the University of Lagos (CMUL), Lagos. This is one of the national reference laboratories designated by the NCDC for COVID-19 testing. Universal safety precautions and handling procedures were carried out as recommended by the Nigerian Centre for Disease Control (NCDC) [38]. All specimen transport containers were disinfected with a 10% hypochlorite solution. Viral agents in specimen aliquots were inactivated in
guanidinium-thiocyanate-based lysis buffer at room temperature for 10 minutes before extraction of viral nucleic acid.

**Nucleic acid extraction and real-time reverse transcriptase polymerase chain reaction**

The viral nucleic acid from inactivated samples were extracted using a mini spin column RNA extraction kit by Qiagen (Qiagen, Germantown, Maryland, United States) in a Class IIA Biological Safety Cabinet according to the manufacturer’s instructions. The purified ribonucleic acid (RNA) was reverse transcribed into cDNA and amplified, using the GeneFinder COVID-19 Plus RealAmp RT-PCR test kit in the Biorad CFX96 Real-Time PCR system.

The GeneFinder™ COVID-19 Plus RealAmp Kit is a real-time reverse transcription polymerase chain reaction (qRT-PCR) test for the qualitative detection of SARS-CoV-2 RdRp, N, and E genes. The SARS-CoV-2 primer and probe set(s) are designed to detect RNA from the SARS-CoV-2. During the amplification process, the probe anneals to a specific target sequence located between the forward and reverse primers. In the extension phase of the PCR cycle, the 5' nuclease activity of Taq DNA polymerase degrades the bound probe, causing the reporter dye to separate from the quencher dye, generating a fluorescent signal. Fluorescence intensity is monitored at each PCR cycle by the maestro software of the Biorad CFX96 Real-Time system.

**Statistical analysis**

Data generated were entered into excel sheets and analyzed using the R Statistical package. Descriptive statistics for categorical variables were presented as number (percent) and for continuous variables as mean ±standard deviation (SD) or median (interquartile range; IQR). Comparison of means was carried out using Student’s t-test and Wilcon signed rank exact test with statistical significance at 0.05. The percentage of positive and negative agreement, positive predictive value (PPV), negative predictive value (NPV), and a 95% confidence interval (CI) were calculated. Kappa coefficient was used to estimate agreement between nasopharyngeal swabs and saliva RT-PCR test results.

**Results**

Although a total of 309 participants were enrolled to provide both swab and saliva specimens, only 299 with valid qRT-PCR results were analyzed in the data set of this study. Samples with valid qRT-PCR are those with target and internal control Cycle threshold values (Ct value) within the kit manufacturer’s acceptable ranges. The 10 samples with invalid qRT-PCR results are both swab and saliva samples which its internal control failed to amplify. The 299 participant specimens analyzed consisted of 159 (53.2%) males and 140 (46.8%) females aged between 8 to 83 years with a mean age of 36.33 (±13.45) years (Table 1). Most of the participants were within active age groups with a frequency of 31.8%, 28.4%, and 18.7% for age groups 20–30, 31–40, and 41–50 years respectively and this was statistically significant (Table 1).

Analysis of the 299 specimens with valid results showed that 39 (13.0%) had detectable SARS-CoV-2 RNA. This comprises 21 (53.8%) males and 16 (46.2%) females with no statistical significance (Table 2). SARS-CoV-2 was detected among all the age groups of the participants with higher frequencies; 22.6%, 20.9%, and 18.2% in age groups <20, 51–60, and 61–70 years respectively with no statistical significance (Table 2).

Both nasopharyngeal swabs and saliva were positive in 20 (51.3%) participants, 10 (25.6%) had swab positive/saliva negative results and 9 (23.1%) had saliva positive/swab negative results.
Table 1. Age and sex distribution of study participants (n = 299).

| Gender | Male | Female | Frequency (%) | X² | P value |
|--------|------|--------|---------------|----|---------|
| Age Group |      |        |               |    |         |
| <20    | 12   | 10     | 22 (7.4)      |    |         |
| 20–30  | 29   | 66     | 95 (31.8)     |    |         |
| 31–40  | 57   | 28     | 85 (28.4)     |    |         |
| 41–50  | 34   | 22     | 56 (18.7)     |    |         |
| 51–60  | 16   | 8      | 24 (8.0)      |    |         |
| 61–70  | 6    | 5      | 11 (3.7)      |    |         |
| >70    | 5    | 1      | 6 (2)         |    |         |
| Total  | 159 (53.2) | 140 (46.8) | 299 (100) |    |         |

The demographic distribution of the two hundred and ninety-nine (299) participants who consented, were enrolled, whose specimens were collected and analyzed by RT-PCR and R Statistical package.

https://doi.org/10.1371/journal.pone.0275201.t001

Table 2. Relationship of SARS-CoV-2 positivity with gender and age groups.

| Gender | Negative (%) | Positive (%) | Total (%) | X² | P value |
|--------|--------------|--------------|-----------|----|---------|
| Female | 122 (46.9)   | 16 (46.2)    | 138 (53.1) |    |         |
| Male   | 138 (53.1)   | 21 (53.8)    | 260 (87)   |    |         |
| Total  | 260 (87)     | 39 (13)      | 299 (100)  |    |         |

The overall distribution and relationships of gender and age groups with the detection of SARS-CoV-2 RNA in the Two hundred and ninety-nine swab and saliva samples using the GeneFinder COVID-19 Plus RealAmp RT-PCR kit analyzed with the Biorad CFX96 Real-Time system.

https://doi.org/10.1371/journal.pone.0275201.t002
Discussion

The percentage of positive and negative agreement of the saliva samples as compared with the nasopharyngeal swab were 67% and 97% respectively. The positive and negative predictive

| Gender | Negative (%) | Positive for Both Methods (%) | Saliva Positive (%) | Nasopharyngeal Swab Positive (%) | Total (%) | X² | P value |
|--------|--------------|-------------------------------|---------------------|----------------------------------|-----------|----|---------|
| Female | 122 (87.1)   | 8 (5.7)                       | 5 (3.6)             | 5 (3.6)                          | 140 (100) | 0.69116 | 0.8753  |
| Male   | 138 (86.8)   | 12 (7.5)                      | 4 (2.5)             | 5 (3.1)                          | 159 (100) |     |         |
| Total  | 260          | 20                            | 9                   | 10                               |           |     |         |

The relationshp between SARS-CoV-2 positivity across the sample types (both nasopharyngeal swab and saliva samples, only saliva or nasopharyngeal samples), gender and age groups using the GeneFinder COVID-19 Plus RealAmp RT-PCR kit analyzed with the Biorad CFX96 Real-Time system.

https://doi.org/10.1371/journal.pone.0275201.t003

Fig 1. Cycle Threshold (Ct) values for SARS-CoV-2 positivity to (A) E-gene, (B) N-gene, and (C) Orf1ab gene respectively, show good comparison on both the Saliva and the Nasopharyngeal swab: The median Cycle Threshold (Ct) values for the three SARS-CoV-2 genes (E, N, and Orf1ab) of the positive samples (Ct < 40) and the negative samples (Ct > 40) from both the nasopharyngeal swab and saliva samples were compared using the Wilcoxon signed rank exact test. The p values of 0.07715, 0.8438, and 0.2293 were determined for the E, N, and Orf1ab genes respectively. There were no statistically significant differences between the median SARS-CoV-2 E-gene, N-gene, and Orf1ab gene Ct values detected for the Nasopharyngeal swab and Saliva samples.

https://doi.org/10.1371/journal.pone.0275201.g001
values were 69% and 96% respectively. The findings from this study indicate that drooling saliva samples have good and comparable diagnostic accuracy to the nasopharyngeal swabs with a moderate percentage of positive agreement and a high percentage of negative agreement. Also, the saliva sample shows good Positive Predictive Values (PPVs), and Negative Predictive Values (NPVs). This suggests that the saliva sample has the potential as an alternate specimen of choice for a nasopharyngeal specimen for the expansion of access to COVID-19 testing in the country.

Presently in Nigeria, 5,441,162 samples had been tested according to the Nigerian Centre for Disease Control (NCDC) COVID-19 microsite [39]. This represents only about 2% of the over 200 million human population documented in the country. Although, since the first case of COVID-19 in Nigeria, various molecular laboratories had been established by the NCDC and stakeholders to expand access to COVID-19 testing across states, local governments, and rural communities. Resources for sample collection are very limited within the country. Thus, testing using saliva samples might be particularly useful in Nigeria which has an enormous population index, limited in-country testing capacity, dwindling economic resources, and political and immigration challenges.

Nasopharyngeal swab samples were generally regarded in many settings as the gold standard for SARS-CoV-2 testing by RT-PCR. The technical difficulties and gaps in know-how, procedural discomfort, risk of exposure (particularly to healthcare workers) and challenges with deployment to rural health facilities and communities are part of the numerous limitations of the use of NP swabs in communities and outpatient care settings [40–42]. The possible introduction of saliva samples into the Nigerian national algorithm for SARS-CoV-2 testing is further justified since saliva-based SARS-CoV-2 testing is already in use in some settings and the United States Food and Drug Administration has issued an emergency use authorization for a saliva-based protocol for SARS-CoV-2 testing [11–15].

The method provides a safe, viable, and cost-effective, sample collection method. Saliva seems to be a highly potential substitute for pharyngeal swab collection as it is easily gotten from patients who are expected to simply spit into a sterile universal container. As immigration restriction measures are relaxed with increased inter and intra countries interactions engineered by trade, commerce, and travel. Increased levels of sampling within our communities might become necessary for the continued surveillance of SARS-CoV-2 and the identification of new clusters of infections. The required increase in testing rates within our communities might only be achieved when alternative, simple, and readily acceptable sampling methods are introduced. Saliva sample collection provides an alternative convenient substitute with a comparable diagnostic efficacy even without the use of a transport medium as documented in this study. Hence, an understanding of the usefulness of saliva in a community-based screening setting is crucial, particularly in asymptomatic individuals.

Our findings aligned with multiple published works supporting saliva as an alternative sample for screening and diagnosis of COVID-19 [5, 9, 21, 42–49]. However, it was at variance with a few other reports where saliva was shown to be more sensitive than the corresponding NPS [50–52]. Participants recruited in this study were asymptomatic individuals residing within the low, medium, and high-density areas in Lagos, Nigeria. Several reasons may account for the discordance in the findings from various studies, which were not evaluated in this study.

Most published works using saliva samples for the detection of SARS-CoV-2 by RT-PCR have been carried out with the recruitment of patients with obvious COVID-19 signs and symptoms or other individuals with suspicious symptoms. While only a few studies had been carried out with cohorts of asymptomatic patients as done in our study. In groups of asymptomatic individuals, the lower sensitivity of saliva samples as compared to nasopharyngeal...
samples for the detection of SARS-CoV-2 RNA has been reported [42, 53–58]. Others with a higher sensitivity to saliva samples have also been documented [46, 54–62].

However, based on the context that the diagnosis of symptomatic and asymptomatic COVID-19 illness has several discrepant determinants depending on the type of clinical specimen type and variation in temporal viral shedding apart from the diagnostic primer/probe mismatches with infecting SARS-CoV2 virus sequence [9, 32, 45–48, 53]. The type of samples (saliva or nasopharyngeal swab) and the timing of collection for testing deserve careful consideration because these may affect the diagnostic accuracy of saliva and nasopharyngeal swab testing differentially [48, 50, 52, 54, 58, 61, 62]. Several studies that compared viral load in saliva and nasopharyngeal specimens have reported the detection of a higher viral load of SARS-CoV-2 in saliva than in nasopharyngeal swabs and for longer periods probably since ACE2 cells that cover the salivary gland ducts are the first target of SARS-CoV-2 [9, 32, 45–48, 52, 53, 58, 61, 62]. It is worthy to note that whether certain clinical syndromes influence the specific specimen types for optimal RT-PCR diagnostic accuracy, requires further investigations.

Our findings indicate that drooling saliva samples have good and comparable diagnostic accuracy to the nasopharyngeal swabs with moderate sensitivities and high specificities. However, the population studied were mainly young and middle-aged individuals who were either asymptomatic or had mild signs and symptoms but with the ease of use and good diagnostic performance, testing for the detection of SARS-CoV-2 using a saliva sample is recommended.

Conclusion

Our study adds to the growing body of evidence supporting saliva as an attractive, alternative, sensitive, and less invasive sample collection method for SARS-CoV-2 RNA detection. It also highlights the possibilities of a self-collected saliva sampling method. With the added advantages of this alternate sampling approach being less invasive and technically less demanding, it would facilitate the efficient scaling up of SARS-CoV-2 testing capacities in community settings by enhancing acceptability and accessibility in a local community setting.

Supporting information

S1 File. Raw data and analysis.
(XLSX)

S2 File.
(DOCX)

S3 File. Saliva all positive figures.
(XLS)

Acknowledgments

The authors would like to acknowledge and thank all individuals who volunteered to be part of this study and health personnel involved in the collection and transportation of samples from the Lagos University Teaching Hospital (LUTH) sample collection site. The laboratory scientists of the Centre for Human and Zoonotic Virology (CHAZVVY), College of Medicine, University of Lagos (CMUL) are also acknowledged for assisting in sample analysis. All authors and manuscripts cited in the reference section are also acknowledged for making their publications available for use publicly.
Author Contributions

**Conceptualization:** Olumuyiwa Babalola Salu, Iorhen Ephraim Akase, Roosevelt Amaobichukwu Anyanwu, Mercy Remilekun Orenolu, Maryam Abiodun Abdullah, Temie Giwa-Tubosun, Sodiq Abiodun Oloko, Ayomide Michael Oshinjo, Aisha Ajoke Abiola, Kolawole Solomon Oyedeji, Sunday Aremu Omilabu.

**Data curation:** Olumuyiwa Babalola Salu, Iorhen Ephraim Akase, Roosevelt Amaobichukwu Anyanwu, Kolawole Solomon Oyedeji.

**Formal analysis:** Olumuyiwa Babalola Salu.

**Methodology:** Olumuyiwa Babalola Salu, Iorhen Ephraim Akase, Roosevelt Amaobichukwu Anyanwu, Mercy Remilekun Orenolu, Maryam Abiodun Abdullah, Temie Giwa-Tubosun, Sodiq Abiodun Oloko, Ayomide Michael Oshinjo, Aisha Ajoke Abiola, Kolawole Solomon Oyedeji, Sunday Aremu Omilabu.

**Project administration:** Olumuyiwa Babalola Salu.

**Supervision:** Olumuyiwa Babalola Salu.

**Validation:** Olumuyiwa Babalola Salu.

**Writing – original draft:** Olumuyiwa Babalola Salu, Iorhen Ephraim Akase, Roosevelt Amaobichukwu Anyanwu, Mercy Remilekun Orenolu, Maryam Abiodun Abdullah, Temie Giwa-Tubosun, Sodiq Abiodun Oloko, Ayomide Michael Oshinjo, Aisha Ajoke Abiola, Kolawole Solomon Oyedeji, Sunday Aremu Omilabu.

**Writing – review & editing:** Olumuyiwa Babalola Salu, Iorhen Ephraim Akase, Roosevelt Amaobichukwu Anyanwu, Mercy Remilekun Orenolu, Maryam Abiodun Abdullah, Temie Giwa-Tubosun, Sodiq Abiodun Oloko, Ayomide Michael Oshinjo, Aisha Ajoke Abiola, Kolawole Solomon Oyedeji, Sunday Aremu Omilabu.

References

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727–33. https://doi.org/10.1056/NEJMoa2001017 PMID: 31978945

2. World Health Organization (WHO). Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19), 2020. https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf. Accessed on 27 August 2020.

3. Uddin M, Mustafa F, Rizvi TA, Loney T, Suwaidi HA, Al-Marzouqi AH, et al. SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions. Viruses. 2020 May 10; 12(5):526. https://doi.org/10.3390/v12050526 PMID: 32397688.

4. Senok A, Alsuwaidi H, Atrah Y, Al Ayedi O, Al Zahid J, Han A, et al. Saliva as an Alternative Specimen for Molecular COVID-19 Testing in Community Settings and Population-Based Screening. Infection and drug resistance, 2020; 13, 3393–3399. https://doi.org/10.2147/IDR.S275152 PMID: 33061486

5. Chan JF, Yip CC, To KK, Tang TH, Wong SC, Leung KH, et al. Improved Molecular Diagnosis of COVID-19 by the Novel, Highly Sensitive and Specific COVID-19-RdRp/HeI Real-Time Reverse Transcription-PCR Assay Validated In Vitro and with Clinical Specimens. J Clin Microbiol. 2020 Apr 23; 58(5): e00310–20. https://doi.org/10.1128/JCM.00310-20 PMID: 32123196.

6. Khurshid Z, Asiri FYI, Al Wadaani H. Human saliva: non-invasive fluid for detecting novel coronavirus (2019-nCoV). Int J Environ Res Public Health. 2020; 17(7):2225.

7. Adhikari SP, Meng S, Wu YJ, Mao YP, Ye RX, Wang QZ, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention, and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty. 2020; 9(1):1–12.

8. Loeffelholz MJ, Tang YW. Laboratory diagnosis of emerging human coronavirus infections—the state of the art. Emerging Microbes Infect. 2020; 9(1):747–56. https://doi.org/10.1080/22221751.2020.1745095 PMID: 32196430
9. To KK-W, Tsang OT-Y, Leung W-S, Tam AR, Wu T-C, Lung DC, et al. Temporal profiles of viral load in posterior oropharyngeal swab samples and serum antibody responses during infection with SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020; 20(5):565–574. https://doi.org/10.1016/S1473-3099(20)30196-1 PMID: 32213337
10. Hong KH, Lee SW, Kim TS, Huh HJ, Lee J, Kim SY, et al. Guidelines for Laboratory Diagnosis of Coronavirus Disease 2019 (COVID-19) in Korea. Ann Lab Med. 2020 Sep; 40(5):351–60. https://doi.org/10.3343/alm.2020.40.5.351 PMID: 32372728
11. Weichsel A. Goodbye, nasal swabs: B.C. announces non-invasive COVID-19 test for students. CTV News. 17 September 2020. Accessed at https://bc.ctvnews.ca/goodbye-nasal-swabs-b-c-announces-non-invasive-covid-19-test-for-students-1.5109803 on 20 September 2020.
12. Sataline S. Hong Kong’s key to keeping COVID out is in its airport. Intelligencer. 24 August 2020. Accessed at https://nymag.com/intelligencer/2020/08/hong-kongs-key-to-keeping-covid-out-is-in-its-airport.html on 20 September 2020.
13. University of Chicago. On-campus COVID-19 testing dashboard. Accessed at https://splunk-public.machinedata.illinois.edu/en-US/app/uofi_shield_public_APP/home on 20 September 2020.
14. Vogels CBF, Watkins AE, Harden CA, Brackney DE, Shafer J, Wang J, et al. Saliva Direct: a simplified and flexible platform to enhance SARS-CoV-2 testing capacity. medRxiv. Preprint posted online on 28 September 2020. https://doi.org/10.1101/2020.08.03.20167791
15. U.S. Food and Drug Administration. Coronavirus (COVID-19) update: FDA issues Emergency Use Authorization to Yale School of Public Health for Saliva Direct, which uses a new method of saliva sample processing. 15 August 2020. Accessed at www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-FDA-issues-emergency-use-authorization-yale-school-public-health on 20 September 2020.
16. Granger DA, Kivilghan KT, Fortunato C, Harmon AG, Hibel LC, Schwartz EB, et al. Integration of saliva vary biomarkers into developmental and behaviorally oriented research: problems and solutions for collecting specimens. Physiol Behav. 2007 Nov; 92(4):583–90. https://doi.org/10.1016/j.physbeh.2007.05.004 PMID: 17572453
17. Fakheran O, Dehghannejad M, Khademi A. Saliva as a diagnostic specimen for detection of SARS-CoV-2 in suspected patients: a scoping review. Infect Dis Poverty 2020; 9: 100. https://doi.org/10.1186/s40249-020-00728-w PMID: 32698862
18. Kapoor P, Chowdhry A, Kharbanda OP, Popli DB, Gautam K, Saini V. Exploring salivary diagnostics in COVID-19: a scoping review and research suggestions. BDJ Open 7, 8 (2021). https://doi.org/10.1038/s41485-021-00064-7 PMID: 33509385
19. Pasomsub E, Watcharananan SP, Boonyawat K, Janchompoo P, Wongtabtim G, Sukusuwan W, et al. Saliva sample as a non-invasive specimen for the diagnosis of coronavirus disease-2019 (COVID-19): a cross-sectional study. Clin Microbiol Infect. 2020. https://doi.org/10.1016/j.cmi.2020.05.001 PMID: 32422408
20. Skolimowska K, Rayment M, Jones R, Madona P, Moore LS, Randell P. Non-invasive saliva specimens for the diagnosis of COVID-19: caution in mild outpatient cohorts with low prevalence. Clin Microbiol Infect. 2020. https://doi.org/10.1016/j.cmi.2020.07.015 PMID: 32680869
21. Williams E, Bond K, Zhang B, Putland M, Williamson DA, McAdam AJ. Saliva as a non-invasive specimen for detection of SARS-CoV-2. J Clin Microbiol. 2020; 58(8): e00776–e00720. https://doi.org/10.1128/JCM.00776-20 PMID: 32317257
22. Wang Y, Upadhya A, Pillai S, Khayambashi P, Tran SD. Saliva as a diagnostic specimen for SARS-CoV-2 detection: A scoping review. Oral Dis. 2022 Apr 21. Epub ahead of print. https://doi.org/10.1111/odi.14216 PMID: 35445491.
23. Nacher M, Mergeay-Fabre M, Blanchet D, Benoit O, Pozl T, Mesphoule P, et al. Diagnostic accuracy, and acceptability of molecular diagnosis of COVID-19 on saliva samples relative to nasopharyngeal swabs in tropical hospital and extra-hospital contexts: The COVISAL study. PLOS ONE. 2021: 16(9): e0257169. https://doi.org/10.1371/journal.pone.0257169 PMID: 34516569
24. Nacher M, Mergeay-Fabre M, Blanchet D, Benoit O, Pozl T, Mesphoule P, et al. Prospective comparison of saliva and nasopharyngeal swab sampling for mass screening for COVID-19. Frontiers in Medicine. 2021; 8, 621160. https://doi.org/10.3389/fmed.2021.621160 PMID: 33708779
25. Al Suwaidi H, Senok A, Varghese R, Deesi Z, Khansheh H, Pokasirakath S, et al. Saliva for molecular detection of SARS-CoV-2 in school-age children. Clinical Microbiology & Infection. 2021; 27(9), 1330–1335. https://doi.org/10.1016/j.cmi.2021.02.009 PMID: 33618013
26. Alkhateeib KJ, Cahill MN, Ross AS, Arnold FW, Snyder JW. The reliability of saliva for the detection of SARS-CoV-2 in symptomatic and asymptomatic patients: Insights on the diagnostic performance and utility for COVID-19 screening. Diagnostic Microbiology & Infectious Disease. 2021; 101(3), 115450. https://doi.org/10.1016/j.diagmicrobio.2021.115450 PMID: 34284319
27. Altawalah H, AlHuraish F, Alkanda RI, Ezzikouri S. Saliva specimens for detection of severe acute respiratory syndrome coronavirus 2 in Kuwait: A cross-sectional study. Journal of Clinical Virology. 2020; 132, 104652. https://doi.org/10.1016/j.jcv.2020.104652 PMID: 33053493

28. Amendola A, Sberna G, Lalle E, Colavita F, Castilletti C, Menchini G, et al. Saliva is a valid alternative to nasopharyngeal swab in chemiluminescence-based assay for detection of SARS-CoV-2 antigen. Journal of Clinical Medicine. 2021; 10(7), 1471. https://doi.org/10.3390/jcm10071471 PMID: 33918294

29. Ana Laura GO, Abraham Josué NR, Briceida LM, Israel PO, Tania AF, Nancy MR, et al. Sensitivity of the molecular test in saliva for detection of COVID-19 in pediatric patients with concurrent conditions. Frontiers in Pediatrics. 2021; 9, 642781. https://doi.org/10.3389/fped.2021.642781 PMID: 33912522

30. Atieh MA, Guirguis M, Alsabeeha NHM, Cannon RD. The diagnostic accuracy of saliva testing for SARS-CoV-2: A systematic review and meta-analysis. Oral Diseases. 2021. https://doi.org/10.1111/odi.13934 PMID: 34080272

31. Palíkša S, Lopeta M, Belevičius J, Kurmauskaitė V, Asmenavičiūtė I, Pereckaitė L, et al. Saliva testing is a robust non-invasive method for SARS-CoV-2 RNA detection. Infection & Drug Resistance. 2021; 14, 2943–2951. https://doi.org/10.2147/IDR.S314491 PMID: 34349529

32. Czumbeł LM, Kiss S, Farkas N, Mandel I, Hegyi A, Nagy Á, et al. Saliva as a Candidate for COVID-19 Diagnostic Testing: A Meta-Analysis. Front Med (Lausanne). 2020 Aug 4; 7: 465. https://doi.org/10.3389/fmed.2020.00465 PMID: 32903849.

33. Landry ML, Criscuolo J, Peaper DR. Challenges in use of saliva for detection of SARS-CoV-2 RNA in symptomatic outpatients. J Clin Virol. 2020 Sep; 130. https://doi.org/10.1016/j.jcv.2020.104567 PMID: 32750665.

34. Miranda-Ortiz H, Fernández-Figueroa EA, Ruíz-García EB, Muñoz-Rivas A, Méndez-Pérez A, Méndez-Galván J, et al. Development of an alternative saliva test for diagnosis of SARS-CoV-2 using TriZol: Adapting to countries with lower incomes looking for a large-scale detection program. PLOS ONE 2021; 16(8): e0255807. https://doi.org/10.1371/journal.pone.0255807 PMID: 34407100

35. Chong CY, Kam KQ, Li J. Saliva is not a useful diagnostic specimen in children with Coronavirus Disease 2019. Clin Infect Dis. 2020 Sep 14: ciaa1376. https://doi.org/10.1093/cid/ciaa1376 PMID: 32927475.

36. Kam K, Yung CF, Maiwald M. Clinical utility of buccal swabs for SARS-CoV-2 detection in covid-19-infected children. Journal of the Pediatric Infectious Diseases Society. July 2020; 9(issue 3):370–372.

37. A, b, c, d, e, f, g "College of Medicine, University of Lagos". University of Lagos. Retrieved 15 October 2020.

38. Nigerian Centre for Disease Control (NCDC) Interim Guidance version 2: Infection Prevention and Control recommendations during Health Care provision for suspected and confirmed cases of COVID-19. September 2020.

39. Nigerian Centre for Disease Control (NCDC) Coronavirus COVID-19 microsite (2022). http://covid19.ncdc.gov.ng. Accessed September 5 2022.

40. Marty FM, Chen K, Verrill KA. How to obtain a nasopharyngeal swab specimen. N Engl J Med 2020; 382: e76. https://doi.org/10.1056/NEJMc201260 PMID: 32302471

41. Karligkiotis A, Arosio A, Castelnuevo P. How to obtain a nasopharyngeal swab specimen. N Engl J Med 2020; 383: e14. https://doi.org/10.1056/NEJMc2015949 PMID: 32469474

42. Tsang NNY, So HC, Ng KY, Cowling BJ, Leung GM, Ip DKM. Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a systematic review and meta-analysis. Lancet Infect Dis. 2021 Sep; 21(9):1233–1245. Epub 2021 Apr 12. https://doi.org/10.1016/S1473-3099(21)00146-8 PMID: 33857405.

43. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020; 323(18):1843–1844. https://doi.org/10.1001/jama.2020.3786 PMID: 32159775

44. Yang Y, Yang M, Shen C, Wang F, Yuan J, Li J, et al. Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections. medRxiv. 2020; 2020:2002.2011.

45. Zheng S, Fan J, Yu F, Feng B, Lou B, Zou Q, et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. BMJ. 2020 Apr 21; 369:m1443. https://doi.org/10.1136/bmj.m1443 PMID: 32317267.

46. Azzi L, Carcano G, Gianfagna F, Grossi P, Gasperina DD, Genoni A, et al. Saliva is a reliable tool to detect SARS-CoV-2. J Infect. 2020; 81(1): e45–e50. https://doi.org/10.1016/j.jinf.2020.04.005 PMID: 32298676
47. Jamal AJ, Mozafarinshahin M, Coomes E, Powis J, Li AX, Paterson A, et al. Sensitivity of nasopharyngeal swabs and saliva for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa848 PMID: 32584972

48. Nagura-Iked a M, Imai K, Tabata S, Miyoshi K, Murahara N, Mizuno T, et al. Clinical evaluation of self-collected saliva by RT-qPCR, direct RT-qPCR, RT-LAMP, and a rapid antigen test to diagnose COVID-19. J. Clin. Microbiol. https://doi.org/10.1128/JCM.01438-20 (2020). PMID: 32636214

49. Teo AKJ, Choudhury Y, Tan IB, Cher CY, Chew SH, Wan ZY, et al. Saliva is more sensitive than nasopharyngeal or nasal swabs for diagnosis of asymptomatic and mild COVID-19 infection. Sci Rep. 2021 Feb 4; 11(1):3134. Erratum in: Sci Rep. 2021 Jun 9;11(1):12538. https://doi.org/10.1038/s41598-021-82784-z PMID: 33542443.

50. Leung EC, Chow VC, Lee M K, Lai RW. Deep throat saliva as an alternative diagnostic specimen type for the detection of SARS-CoV-2. J. Med. Virol. https://doi.org/10.1002/jmv.26258 (2020). PMID: 32621616

51. Wong SCY, Tse H, Siu HK, Kwong TS, Chu MY, Yau FYS, et al. Posterior oropharyngeal saliva for the detection of severe acute respiratory syndrome coronavirus 2 (SARCov-2). Clin. Infect. Dis. 71, 2939. https://doi.org/10.1093/cid/ciaa797 (2020). PMID: 32625444

52. Wyllie AL, Fournier J, Casanovas-Massana A, Campbell M, Tokuyama M, Vijayakumar P, et al. Saliva is more sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs. medRxiv. 2020. 2020:2004.2016.

53. Cauley L, Corsten M, Eapen L, Whelan J, Angel JB, Antonation K, et al. Salivary detection of COVID-19. Ann Intern Med 2020 [epub ahead of print 28 Aug 2020]. https://doi.org/10.7326/M20-4738 PMID: 32625791

54. Bastos ML, Perlman-Arrow S, Menzies D, Campbell JR. The Sensitivity and Costs of Testing for SARS-CoV-2 Infection with Saliva Versus Nasopharyngeal Swabs: A Systematic Review and Meta-analysis. Ann Intern Med. 2021 Apr; 174(4):501–510. Epub 2021 Jan 12. Erratum in: Ann Intern Med. 2021 Apr;174(4):584. https://doi.org/10.7326/M20-6569 PMID: 33428446.

55. Caixeta DC, Oliveira SW, Cardoso-Sousa L, Cunha TM, Goulart LR, Martins MM, et al. One-Year Update on Salivary Diagnostic of COVID-19. Front. Public Health. 2021; 9, 589564. https://doi.org/10.3389/fpubh.2021.589564 PMID: 34150692

56. Ota K, Yanagihara K, Sasaki D, Kaku N, Uno N, Sakamoto K, et al. Detection of SARS-CoV-2 using qRT-PCR in saliva obtained from asymptomatic or mild COVID-19 patients, comparative analysis with matched nasopharyngeal samples. PLoS ONE. 2021; 16(6): e0252964. https://doi.org/10.1371/journal.pone.0252964 PMID: 34111203

57. Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet [Internet]. 2020 Feb 11; 395(10223):514–23. Available from: https://academic.oup.com/jid/article/221/11/1757/5739751 https://doi.org/10.1016/S0140-6736(20)30154-9 PMID: 31986261.

58. Butler-Laporte G, Lawandi A, Schiller I, Yao MC, Dendukuri N, McDonald EG, et al. Comparison of Saliva and Nasopharyngeal Swab Nucleic Acid Amplification Testing for Detection of SARS-CoV-2: A Systematic Review and Meta-analysis. JAMA Intern Med. 2020;1–8.

59. Chau NVV, Lam VT, Dung NT, Yen LM, Minh NNO, Hung LM, et al. The natural history and transmission potential of asymptomatic SARS-CoV-2 infection. Clin Infect Dis. 2020; 71(10):2679–2687.

60. Migueres M, Mengelle C, Dimeglio C, Didier A, Alvarez M, Delobel P, et al. Saliva sampling for diagnosing SARS-CoV-2 infections in symptomatic patients and asymptomatic carriers. J Clin Virol. 2020; 130:104580. https://doi.org/10.1016/j.jcv.2020.104580 PMID: 32781366

61. Azzi L, Maurino V, Baj A, Dani M, d’Aiuto A, Fasano M, et al. Diagnostic Salivary Tests for SARS-CoV-2. J Dent Res. 2021 Feb; 100(2):115–123. Epub 2020 Oct 31. https://doi.org/10.1177/0022034520969670 PMID: 33151366.

62. Nasiri K, Dimitrova A. Comparing saliva and nasopharyngeal swab specimens in the detection of COVID-19: A systematic review and meta-analysis. J Dent Sci. 2021 Jul; 16(3):793–805. Epub 2021 Jan 29. https://doi.org/10.1016/j.jds.2021.01.010 PMID: 33558826.